Why Intra-Cellular Therapies (ITCI) Is Skyrocketing Now
We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where Intra-Cellular Therapies (NASDAQ:ITCI) stands against the other ...
Hosted on MSN29d
ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz
Shares of Intra-Cellular Therapies ITCI rallied 14.9% on Friday after the company announced that it has entered into a settlement agreement with Sandoz SDZNY regarding the Caplyta (lumateperone ...
Steady M&A Deals to Begin 2025, Disappointing IPOs So Far
Investors rooting for increased M&A and a flurry of IPOs will have to be patient as Q1 tracks with continued low counts on ...
Morgan Stanley Remains a Hold on Intra-Cellular Therapies (ITCI)
In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on Intra-Cellular Therapies (ITCI – Research Report), ...
J.P. Morgan Remains a Buy on Intra-Cellular Therapies (ITCI)
In a report released on January 27, Jessica Fye from J.P. Morgan maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), ...
Nasdaq28d
ITCI Crosses Above Average Analyst Target
In recent trading, shares of Intra-Cellular Therapies Inc (Symbol: ITCI) have crossed above the average analyst 12-month target price of $101.27, changing hands for $127.19/share. When a stock ...